Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Castration Sensitive Prostate Cancer Clear all
Recruiting Phase 2 Interventional

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

NCT07216248
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

NCT04191096
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Recruiting Phase 3 Interventional

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
374
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Early Phase 1 Interventional

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT03511196
View directory record Official record
Conditions
Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Early Phase 1 Interventional

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

NCT05683964
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

NCT02058706
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Recruiting No phase listed Observational

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

NCT07406282
View directory record Official record
Conditions
Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer
Interventions
Darolutamide, Abiraterone acetate, Enzalutamide, Apalutamide
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

NCT05189457
View directory record Official record
Conditions
Prostate Cancer, Stage IV Prostate Cancer
Interventions
Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel, Tislelizumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906
View directory record Official record
Conditions
Biochemically Recurrent Prostate Cancer
Interventions
Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel
Drug
Lead sponsor
ORIC Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Jeffersonville, Indiana • Charlotte, North Carolina • Canton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622
View directory record Official record
Conditions
Prostate Cancer
Interventions
talazoparib plus enzalutamide, Placebo plus enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Terminated Phase 1 Interventional

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

NCT05733351
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

NCT01875250
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi)
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 2 Interventional

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

NCT04335682
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
Interventions
Darolutamide, Enzalutamide
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
326
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 15, 2026, 11:02 PM EDT
Recruiting Phase 1 Interventional

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

NCT06044025
View directory record Official record
Conditions
Castration Sensitive Prostate Cancer
Interventions
Metformin, Turmeric
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 15, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Nonmetastatic prOstAte With BRCAness

NCT03533946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Rucaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

NCT03899467
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
GT0918
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Athens, Georgia • Louisville, Kentucky • Towson, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 15, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT04288687
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 15, 2026, 11:02 PM EDT